Peer Exchange

Five medical provide insights around breakthrough treatment strategies in relapsed/recurrent DLBCL.

John Marshall, MD; Al B. Benson III, MD, FACP, FACCC, FASCO; Kristen Ciombor, MD, MSCI; Stacey Cohen, MD, and Marwan Fakih, MD, examine the landscape of second-line and third-line treatments for metastatic colorectal cancer, along with recent advancements in managing the disease.

Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

Guillermo Garcia-Manero, MD; Rami Komrokji, MD; Esther Natalie Oliva, MD; Amer Zeidan, MBBS, MHS, and Dr Thomas Cluzeauprovide expert insights on the latest developments in Lower-Risk Myelodysplastic Syndromes (LR-MDS) as presented at the European Hematology Association (EHA) 2024 conference.

Medical experts in small cell lung cancer convene to examine first-line treatments, ongoing clinical trials, and emerging therapies shaping the evolving treatment landscape.

A panel of medical experts reviews the latest advances in managing and treating renal cell carcinoma (RCC) and non-clear cell renal cell carcinoma (nccRCC), discussing recent trial data and sharing insights from their clinical practices.

Mark Socinski, MD; Helena A. Yu, MD; Zosia Piotrowska, MD, MHS; Julia Rotow, MD, and Benjamin Levy, MD,discuss the current standard of care, emerging data on novel therapies such as antibody-drug conjugates (ADCs) and clinical trials, patient selection considerations, and practical guidance foroptimizing patient care.

Kelly McCann, MD, PhD, drives a discussion surrounding key topics and highlights in HR+ breast cancer treatment as presented at ASCO 2024.

A panel of experts on HER2+ breast cancer has a comprehensive discussion on recent data updates and how they might impact clinical practice.

Lori Wirth, MD, moderates a panel of medical experts specializing in radioactive iodine-refractory differentiated thyroid cancer (RAI-refractory DTC), discussing current treatments and ongoing clinical trials in this field.

A panel of experts on colorectal cancer provides comprehensive insights on MRD testing within the disease space, highlight the general landscape, recent data, ongoing trials, and future directions.

A panel of thoracic oncologists have a comprehensive discussion on the treatment of HER2 non–small cell lung cancer, covering diagnosis, therapies, clinical trials, and unmet needs in the treatment space.

Following ASCO GU 2024, a panel of GU medical oncologists discuss recent updates in bladder cancer and provide comprehensive insights on the evolving treatment landscape.

Aparna Parikh, MD, leads a panel discussion surrounding updates and advancements in the metastatic colorectal cancer treatment landscape.

A panel of medical oncologists specializing in the treatment of renal cell carcinoma have a comprehensive discussion on updates in the treatment of advanced RCC following ASCO GU 2024.

A panel of medical experts discuss key highlights from ASCO GI 2024 surrounding the hepatocellular carcinoma (HCC) treatment landscape.

Drs Yi-Bin Chen, Corey Cutler, Hannah Choe, and Mitchell Horwitz discuss current and emerging treatment landscape of chronic graft-versus-host disease (GVHD). They examine treatment selection in different lines of therapies and the near future landscape of treatment when newer mechanisms of action become available for GVHD.

A panel of experts discuss recent data updates on the treatment and management of HER2+ breast cancer and how these data may impact practice.